Neutrophilic Dermatosis in Myelodysplastic Syndrome and Chronic Active Hepatitis C

Sharma, Rupam; Johnson, Royce H.; Heidari, Arash; Malerich, Matthew M.; Stull, William R; Cobos, Everardo

doi:10.1177/23247096211037458

Cited by 2 publications

(1 citation statement)

References 21 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several patients with HCV, HSV-1, and HSV-2 were identified. The association between HCV and ND has been reported, although due to limited evidence, it has been difficult to determine whether HCV truly increases the risk of ND [12][13][14]. Herpes infections have only been rarely reported in those with ND [15].…”

Section: Discussionmentioning

confidence: 99%

Drug-Induced and Malignancy-Associated Neutrophilic Dermatoses in Patients with Hematologic Malignancies: A Single Institution Experience

deCampos-Stairiker,

Kody,

Meyers

et al. 2024

Dermatology

View full text Add to dashboard Cite

Introduction: Neutrophilic dermatoses (NDs) often occur secondary to inflammatory conditions, medication exposure, and hematologic malignancy. While malignancy-associated NDs (MA-NDs) have been well-reported among those with hematologic cancers, little is known about drug-induced NDs (DI-NDs) within this population. The objective of this study is to compare the presentations and outcomes of patients with hematologic malignancies who developed MA-NDs and DI-NDs. Methods: Cases of neutrophilic dermatosis (ND) occurring between 2013 and 2023 among those with hematologic malignancies were identified from the electronic medical records of our institution. Patient characteristics, recent medication exposures, cancer mutations, and disease outcomes were reviewed. Patients were categorized with drug-induced ND (DI-ND) if they were recently exposed to one of four medications known to be commonly associated with ND or were otherwise categorized with malignancy-associated ND (MA-ND). We report a descriptive analysis of cases of DI-ND and MA-ND. Results: We identified 52 patients with ND and co-occurring hematologic malignancy including 16 cases of DI-ND (30.8%) and 36 cases of MA-ND (69.2%). The most common ND in both groups was Sweet’s syndrome. Chronic underlying conditions including solid tumors, inflammatory disorders, chronic viral infection, and tobacco use were more common among those with MA-ND. Among those with DI-ND, tyrosine kinase inhibitors were the most commonly associated drugs (43.8%). The most common cancer mutation among those with DI-ND was FLT3 (43.8%) while the most common mutation among those with MA-ND was TP-53 (19.4%). Among those who had died at the time of data collection, 90.0% of those with DI-ND and 66.7% of those with MA-ND died within one year of ND diagnosis. Conclusion: Most cases of ND occurring with hematologic malignancies develop secondary to cancer rather than drug exposure. Different cancer mutations may predispose to DI-ND and MA-ND. Further research is needed to establish diagnostic criteria for DI-ND and to determine the pathogenic role of specific cancer mutations, particularly FLT3, in the development of ND.

show abstract

Section: Discussionmentioning

confidence: 99%

Drug-Induced and Malignancy-Associated Neutrophilic Dermatoses in Patients with Hematologic Malignancies: A Single Institution Experience

deCampos-Stairiker,

Kody,

Meyers

et al. 2024

Dermatology

View full text Add to dashboard Cite

show abstract

New Practical Aspects of Sweet Syndrome

et al. 2022

View full text Add to dashboard Cite

Sweet syndrome (SS), or acute febrile neutrophilic dermatosis, is an inflammatory, non-infectious skin reaction characterized clinically by tender, erythematous papules/plaques/pustules/nodules commonly appearing on the upper limbs, trunk, and head and neck; histologically, SS is characterized by dense neutrophilic infiltrate in the dermis. SS is accompanied by fever; an elevation of inflammatory markers (e.g., erythrocyte sedimentation rate, C reactive protein) in serum may also be observed. Although most cases of SS are idiopathic, SS also occurs in the setting of malignancy or following administration of an associated drug. SS has also been reported in association with pregnancy and a burgeoning list of infectious (most commonly upper respiratory tract infections) and inflammatory diseases; likewise, the litany of possible iatrogenic triggers has also grown. Over the past several years, a wider spectrum of SS presentation has been realized, with several reports highlighting novel clinical and histological variants. Corticosteroids continue to be efficacious first-line therapy for the majority of patients with SS, although novel steroid-sparing agents have been recently added to the therapeutic armamentarium against refractory SS. New mechanisms of SS induction have also been recognized, although the precise etiology of SS still remains elusive. Here, we catalogue the various clinical and histological presentations of SS, summarize recently reported disease associations and iatrogenic triggers, and review treatment options. We also attempt to frame the findings of this review in the context of established and emerging paradigms of SS pathogenesis.

show abstract

Neutrophilic Dermatosis in Myelodysplastic Syndrome and Chronic Active Hepatitis C

Cited by 2 publications

References 21 publications

Drug-Induced and Malignancy-Associated Neutrophilic Dermatoses in Patients with Hematologic Malignancies: A Single Institution Experience

Drug-Induced and Malignancy-Associated Neutrophilic Dermatoses in Patients with Hematologic Malignancies: A Single Institution Experience

New Practical Aspects of Sweet Syndrome

Contact Info

Product

Resources

About